TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60 (Q2867071)
Jump to navigation
Jump to search
Project Q2867071 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60 |
Project Q2867071 in Portugal |
Statements
25,000.0 Euro
0 references
50,000.0 Euro
0 references
50.0 percent
0 references
1 April 2020
0 references
1 April 2023
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
40°12'40.28"N, 8°25'46.06"W
0 references
O projeto TERAPI4 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças amiloides raras de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química NT60 desenvolvida pela BSIM Therapeutics. (Portuguese)
0 references
The TERAPI4 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare amyloid transthyretin diseases. These new compounds are small molecules belonging to the NT60 chemical series developed by BSIM Therapeutics. (English)
7 July 2021
0 references
Le projet TERAPI4 vise à protéger les droits de propriété intellectuelle d’une nouvelle classe d’agents thérapeutiques contre les rares maladies amyloïdes transthyrétines. Ces nouveaux composés sont de petites molécules appartenant à la série chimique NT60 développée par BSIM Therapeutics. (French)
4 December 2021
0 references
Das Projekt TERAPI4 zielt darauf ab, die Rechte des geistigen Eigentums einer neuen Klasse von therapeutischen Wirkstoffen gegen seltene Transthyretin-Amyloiderkrankungen zu schützen. Diese neuen Verbindungen sind kleine Moleküle der von BSIM Therapeutics entwickelten NT60-Chemikalienserie. (German)
13 December 2021
0 references
Het TERAPI4-project heeft tot doel de intellectuele eigendomsrechten van een nieuwe klasse van therapeutische middelen te beschermen tegen zeldzame transthyretine amyloïdenziekten. Deze nieuwe verbindingen zijn kleine moleculen die behoren tot de NT60 chemische serie ontwikkeld door BSIM Therapeutics. (Dutch)
18 December 2021
0 references
Il progetto TERAPI4 mira a proteggere i diritti di proprietà intellettuale di una nuova classe di agenti terapeutici contro le rare malattie amiloidi transtiretina. Questi nuovi composti sono piccole molecole appartenenti alla serie chimica NT60 sviluppata da BSIM Therapeutics. (Italian)
17 January 2022
0 references
El proyecto TERAPI4 tiene como objetivo proteger los derechos de propiedad intelectual de una nueva clase de agentes terapéuticos contra las enfermedades raras de amiloide transtiretina. Estos nuevos compuestos son pequeñas moléculas pertenecientes a la serie química NT60 desarrollada por BSIM Therapeutics. (Spanish)
20 January 2022
0 references
Coimbra
0 references
Identifiers
CENTRO-01-0247-FEDER-046897
0 references